Zusammenfassung
Die Therapie mit Immunglobulinen ist etwa 100 Jahre alt. Sie begann mit der Entdeckung E. von ßehring’s und O. Kitasako’s (1890), daß sich mit dem Serum eines immunisierten Schafes eine Schutzwirkung gegen Diphthe-rietoxine erzielen läßt [9]. Diese Therapieform wurde als passive Immunisierung bezeichnet. Die in der Folgezeit entwickelten, xenogenen Antiseren gegen zahlreiche Infektionserreger hatten den Nachteil, daß sie rasch zur Immunisierung der Patienten gegen das Fremdeiweiß führten und eine „Serumkrankheit“ auslösten. Neue Wege der Immunglo-bulintherapie eröffneten sich erst, als es Cohn und Mitarbeitern in den vierziger Jahren gelang, im großtechnischen Maßstab menschliche Proteine aus Humanplasma (siehe Kapitel V.) zu gewinnen.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Ammann AJ, Ashman RF, Buckley RH, Hardie WR, Krantmann HJ, Nelson J, Ochs H, Stiehm ER, Tiller T, Wara DW, Wedgwood R (1982) Use of intravenous y-globulin in antibody immunodeficiency: results of a multicenter controlled trial. Clin Immunol Immunopathol 22:60–67.
Arsura EL, Blick A, Brunner NG, Namba T, Grob D (1986) High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med 146:1365–1368.
Atrah HI, Sheehan T, Gribben J, Crawford RJ, O’Donnel JR, Sandilands DP (1986) Improvement of post platelet transfusion increments following intravenous immunoglobulin therapy för leukaemic HLA-immunized patients. Scand J Haematol 36:160–164.
Balzereit F, Fateh-Moghadam A, Besinger KA, Geursen RG (1986) Myasthenia gravis. MMW 128:654–657.
Barandun S, Kistler P, Jeunet F, Isliker H (1962) Intravenous administration of human gamma globulin. Vox Sang 7:157.
Barandun S, Skvaril F, Morell A (1976) Prophylaxe und Therapie mit γ-Globulin. Allgemeine Charakterisierung und klinische Anwendung von γ-Globulin-Präparaten. Schweiz Med Wo-chenschr 106:533–542, 580–586.
Becker T, Panzer S, Maas D, Kiefel V, Sprenger R, Kirschbaum M, Mueller-Eckhardt C (1985) High-dose intravenous immunoglobulin för posttransfusion purpura. Br J Haematol 61:149–155.
Becton DL, Kinney TR, Chaffee S, Kurtzberg J, Friedman HS, Falleta JM (1984) High-dose intravenous immunoglobulin för severe platelet alloimmunization. Pediatrics 74:1120–1123.
Behring E von, Kitasato O (1890) Über das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren. Dtsch Med Wochenschr 16:1113–1114.
Berlin G, Selbing A, Ryden G (1985) Rhesus haemolytic disease treated with high-dose intravenous immunoglobulin. Lancet 1:1153.
Bierling P, Cordonnier C, Rodet M, Vernant JP, Pesce A, Rochant H, Duedari N (1984) High dose intravenous gammaglobulin and platelet transfusions in leukaemic HLA-immunized patients. Scand J Haematol 33:215:220.
Bing DH (1984) Complement interaction with immune serum globulin and immune globulin intravenous. Am J Med 76(3A):19–24.
Burks AW, Sampson HA, Buckley RB (1986) Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med 314:560–564.
Bussel A, Jaisson F, Janvier M, Traulle C (1983) Utilisation des gammaglobulines intraveineuses à fortes doses dans le traitement des anémies hémolytiques auto-immunes. Presse Med 41:2628.
Béris P, Audétat F, Beyner F, Pittet D, Jeanett M, Miescher PA (1985) Hautes doses d’immu-noglobulines par voie intraveineuse pour le traitement des neutropénics „auto-immunes“. Schweiz Med Wochenschr 115:1512–1514.
Clarke C (1983) Prevention of Rh hemolytic disease by immunoglobulin anti-D. Vox Sang 44:396–399.
Collins MS, Roby RE (1984) Protective activity of an intravenous immune globulin (human) enriched in antibody against polysaccharide antigens för Pseudomonas aeruginosa. Am J Med 76(3A):168–174.
Condie RM, O’Reilly RJ (1984) Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Randomized trial in bone marrow transplant recipients. Am J Med 76(3 A): 134–141.
Cooperative Group of Additional Immunoglobulin Therapy in Severe Bacterial Infections (1983) Multicenter randomized controlled trial on the efficacy of additional immunglobulin therapy in cases of diffuse fibrino-purulent peritonitis. Klin Wochenschr 61:445.
Cunningham-Rundles C (1985) Intravenous immune serum globulin in immunodeficiency. Vox Sang 49 (Suppl. 1):8–14.
Day NK, Good RA, Wahn V (1984) Adverse reactions in selected patients following intravenous infusions of gamma globulin. Am J Med 76(3A):8–14.
Derycke M, Dreyfus M, Ropert JC, Tchernia G (1985) Intravenous immunoglobulin för neonatal isoimmune thrombocytopenia. Arch Dis Child 60:667–679.
Editorial (1983) Antiserum för gram-negative bacteraemia. Lancet 1:967–968.
Fateh-Moghadam A, Wick M, Besinger U, Geursen RG (1984) High-dose intravenous gammaglobulin för myasthenia gravis. Lancet 1:848–849.
Fehr J, Hofmann V, Kappeier U (1982) Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 306:1254–1258.
Flik J, Milbradt H, Wahlers T, Schäfers HJ, Ha-verich A (1987) Passagere HIV-Antikörper-Po-sivität bei Herztransplantierten nach wiederholter Applikation eines CMV-Immunoglobulin-präparates. Dtsch Med Wochenschr 112:178–181.
Furth R van, Leijh PCL (1981) Functional interactions of various commercial gammagobulin preparations with staphlococcus aureus and granulocytes. In: Nydegger UE (ed) Immunotherapy, Academic Press, London pp. 181–190.
Furusho K, Nakano H, Shinomiya K, Tamura T, Manabe Y, Kawarano M, Baba K, Kamiya T, Kiyosawa N, Hayashidera T, Hirose O, Yokoy-ama T, Baba K, Mori C (1984) High-dose intravenous gammaglobulin för Kawasaki disease. Lancet 11:1055–1058.
Glinz W, Grob PJ, Nydegger UE, Ricklin T, Stamm F, Stoffel D, Lasance A (1985) Polyvalent immunoglobulins för prophylaxis of bacterial infections in patients following multiple trauma. Intensive Care Med 11:288–294.
Gocke DJ, Raska K Jr, Pollack W, Schwartzer T (1986) HTLV-III antibody in commercial immunoglobulin. Lancet 1:37–38.
Gronski P, Hofstaetter T, Kanzy EJ, Lüben G, Seiler FR (1983) S-sulfonation: a reversible chemical modification of human immunoglobulins permitting intravenous application. I. Physico-chemical and binding properties of S-sulfonated and reconstituted IgG. Vox Sang 45:144–145.
Grundmann R, Thul P, Pichlmaier H (1985) Prophylaktische Immunglobulingabe nach größeren Magenresektionen. Dtsch Med Wochenschr 110:529–533.
Hansi W, Kratzsch G, Heimpel H (1980) Klinische Erfahrungen mit einem neuen intravenös applizierbaren Immunoglobulin-Präparat. Dtsch Med Wochenschr 105:1675–1680.
Heiner DC (1984) Significance of immunoglobulin G subclasses. Am J Med 76:1–6.
Heiner DC (1986) IgG subclass composition of intravenous immunoglobulin preparations: Clinical relevance. Rev Infect Dis 8:374–381.
Heinze E, Thon A, Vetter U, Gaedicke G, Zup-pinger K (1985) Gammaglobulin therapy in 6 newly diagnosed diabetic children. Acta Paediatr Scand 74:605–606.
Hässig A (1986) Intravenous immunoglobulins: pharmacological aspects and therapeutic use. Vox Sang 51:10–17.
Imaizumi A, Suzuki Y, Sato H, Sato Y (1985) Protective effects of human gamma-globulin preparations against experimental aerosol infections of mice with bordetella pertussis. Vox Sang 48:18–25.
Imbach P, Barandun S, d’Apuzzo V, Baumgart-ner C, Hirt A, Morell A, Rossi E, Schöni M, Vest M, Wagner HP (1981) High-dose intravenous gammaglobulin för idiopathic thrombocytopenic purpura in childhood. Lancet 1:1228–1231.
Imbach P, Berchtold W, Hirt A, Mueller-Eck-hardt C, Rossi E, Wagner HP, Gaedicke G, Joller P, Müller B, Barandun S (1985) Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet 11:463–468.
Iwata M, Ajiki Y (1986) Effect of human immunoglobulin preparations on experimental Bordetella pertussis infection in mice. Vox Sang 51:176–181.
Jilg W, Deinhardt F (1985) Immunprophylaxe der Virushepatitis. Dtsch Med Wochenschr 110:728–730.
John TJ, Ninan GT, Rajagopalan MS, John F, Flewett TH, Francis DP, Zuckerman AJ (1979) Epidemic hepatitis B caused by commercial human immunoglobulin. Lancet 1:1074
Jones RJ, Roe EA, Gupta JL (1980) Controlled trial of Pseudomonas immunoglobulin and vaccine in burn patients. Lancet 11:1263–1265.
Jungi TW, Santer M, Lerch PG, Barandun S (1986) Effect of various treatments of gammaglobulin (IgG) för achieving intravenous tolerance on the capacity to interact with human monocyte Fc receptors. A comparative study. Vox Sang 51:18–26.
Just HM, Metzger M, Vogel W, Pelka RB (1986) Einfluß einer adjuvanten Immunglobulinthera-pie auf Infektionen bei Patienten einer operativen Intensiv-Therapie-Station. Klin Wochenschr 64:245–256.
Kekomäki R, Elfenbein G, Gardner R, Graham-Pole J, Mehta P, Gross S (1984) Improved response of patients refractory ro random-donor platelet transfusions by intravenous gamma globulin. Am J Med 76(3A): 199–203.
Laurian Y, Le Bras P, Ellrodt A, Alvin P (1986) Immune thrombocytopenia, gammaglobulin, and seropositivity to the human T-lymphotropic virus type III. Ann Intern Med 105:145.
Lever AML, Brown D, Webster ADB, Thomas HC (1984) Non-A, non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet 11:1062–1964.
Lindquist L, Lundbergh P, Maasing R (1981) Pepsin-treated human gamma globulin in bacterial infections. A randomized study in patients with septicaemia and pneumonia. Vox Sang 40:329–337.
Ludwig H, Knapp W (1980) Erworbene Agammaglobulinämie. Dtsch Med Wochenschr 105:194–201.
Lundblad JL, Mitra G, Sternberg MM, Schroe-der DD (1986) Comparative studies of impurities in intravenous immunoglobulin preparations (Gamimune, Endobulin, Gammagard, Gam-monativ, Immunoglobulin 7S, Intraglobin, San-doglobulin, Venimmun). Rev Infect Dis 8:382–390.
Masuda K, Makula MF, Okuyama K, Ishiyama H, Yasuda J (1982) Antibody spectrum and anticomplementary activity of a plasmin-treated immunoglobulin preparation. Vox Sang 42:8–15.
Masuho Y, Tomibe K, Matsuzawa K, Ohtsu A (1977) Development of an intravenous γ-globulin with Fc activities. I. Preparation and characterization of S-sulfonated human γ-globulin. Vox Sang 32:175–181.
McClelland DB, Yap PL (1984) Clinical use of immunoglobulins. Clin Haematol 13:39–73
McVerry BA, Spearing R, Smith A (1985) SLE anticoagulant: transient inhibition by high dose immunoglobulin infusions. Br J Haematol 61:579–580.
Mollison PL (1983) Blood transfusion in clinical medicine, 7th Edition. Blackwell Scientific Publications, Oxford pp. 187–190.
Morbidity and Mortality Weekly Report (1986) Safety of therapeutic immune globulin preparations with respect to transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus infection. MMWR 35:231–233.
Morell A (1987) Störungen der humoralen Immunität. In: Wahn U, Seger R, Wahn V (ed) Pädiatrische Allergologie und Immunologie in Klinik und Praxis. G. Fischer, Stuttgart.
Morell A, Barandun S (1985) Use of immunoglobulins. In: Das PC (ed) Supportive therapy in haematology, Martinus Nijhoff Publishers, Bo-ston/Dordrecht/Lancester pp. 235–244.
Morell A, Skvaril F (1980) Struktur und biologische Eigenschaften vom Immunglobulinen und γ-Globulin-Präparaten. II. Eigenschaften von γ-Globulin-Präparaten. Schweiz Med Wochenschr 110:80–85.
Morell A, Schürch B, Ryser D, Hofer F, Skvaril F, Barandun S (1980) In vivo behaviour of gamma globulin preparations. Vox Sang 38:272–283.
Morell A, Schnoz M, Barandun S (1982) Buildup and maintenance of IgG serum concentrations with intravenous immunoglobulin in patients with primary humoral immunodeficiency. Vox Sang 43:212–219.
Mueller-Eckhardt C, Küenzlen E (1984) Alloimmune thrombocytopenia of the newborn. In: Engelfriet CP, Loghem JJ van, Borne AEGKr von dem (ed) Immunohematology, Elsevier Science Publishers, B.V., Amsterdam pp. 166–177.
Mueller-Eckhardt C, Salama A, Mahn I, Kiefel V, Neuzner J, Graubner M (1985) Lack of efficacy of high-dose intravenous immunoglobulin in autoimmune haemolytic anaemia: a clue to its mechanism. Scand J Haematol 34:394–400.
Murait Gv, Sidiropoulos D (1981) Intravenous Ig substitution therapy in the treatment of septicemia in preterm neonates. In: Nydegger UE (ed) Immunohemotherapy, Academic Press, London pp. 313–324.
Neu I, Pfaffenrath V, Pelka RB (1980) Klinische und statistische Untersuchungen über den therapeutischen Wert von intrathekal injizierten Immunglobulinen bei infektiös-entzündlichen Erkrankungen des zentralen Nervensystems. Therapiewoche 30:3024–3032.
Newburger Jane W, Takahashi M, Burns JC, Bei-ser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders SP, Shulman ST, Wiggins JW, Hicks RV, Fulton DR, Lewis AB, Leung DYM, Colton T, Rosen FS, Melish ME (1986) The treatment of Kawasaki Syndrome with intravenous gamma globulin. N Engl J Med 315:341–347.
Newland AC (1984) The use of intravenous IgG in immune cytopenias — a review. Apheresis Bulletin 2:13–23.
Newland AC, Macey MG, Bubel M (1984) IgE in intravenous IgG. Lancet 1:1406–1407.
Oxelius V-A (1984) Immunoglobulin G (IgG) subclasses and human disease. Am J Med 76(3A):7–18
Panzer S, Zeitelhuber U, Hach V, Brackmann H, Niessner H, Mueller-Eckhardt C (1986) Immune thrombocytopenia in severe hemophilia A treated with high-dose intravenous immunoglobulin. Transfusion 26:69–72.
Pineda AA, Taswell HF (1975) Transfusion reactions associated with anti-IgA antibodies: report of four cases and review of the literature. Transfusion 15:10–15.
Pirofsky B (1984) Intravenous immune globulin therapy in hypogammaglobulinemia. Am J Med 76(3A):53–60.
Pollack M (1979) Antibody mediated immunity on Pseudomonas disease and its clinical application. In: Alwing BM, Finlayson JS (ed) Immunoglobulins. Characteristics and uses of intravenous preparations, DHHS, p 73.
Pollack S, Cunningham-Rundles C, Smithwick EM, Barandun S, Good RA (1982) High-dose intravenous gamma globulin för autoimmune neutropenia. N Engl J Med 307:253.
Riesen W (1980) Struktur und biologische Eigenschaften von Immunglobulinen und γ-Globulin-Präparaten. I. Struktur und Funktion von Immunglobulinen. Schweiz Med Wochenschr 110:74–79.
Ring J, Duswald KH (1980) Probleme der intravenösen Gammaglobulintherapie. Klin Wochenschr 58:797–809.
Rohr G, Kusterer K, Schule M, Gladisch R, Schwedes U, Teuber J, Usadel KH (1987) Treatment of Crohn’s disease and ulcerative colitis with 7S-immunoglobulin. Lancet 1:170.
Roifman CM, Lederman HM, Lavi S, Stein LD, Levison H, Gelfand EW (1985) Benefit of intravenous IgG replacement in hypogammaglobuli-nemic patients with chronic sinopulmonary disease. Am J Med 79:171–174.
Rosen FS, Cooper MD, Wedgwood RJP (1984) The primary immunodeficiencies (First of two parts). N Engl J Med 311:235–242.
Rosen FS, Cooper MD, Wedgwood RJP (1984) The primary immunodeficiencies (Second of two parts). N Engl J Med 311:300–310.
Römer J, Morgenthaler J-J, Scherz R, Skvaril F (1982) Characterization of various immunoglobulin preparations för intravenous application. I. Protein composition and antibody content. Vox Sang 42:62–73.
Römer J, Späth PJ, Skvaril E, Nydegger UE (1982) Characterization of various immunoglobulin preparations för intravenous application. II. Complement activation and binding to staphylococcus protein A. Vox Sang 42:74–80.
Scheiermann N, Gesemann M, Riffelmann HD (1985) Nachweis von Anti-HTLV-III-Antikör-pern in Gammaglobulinpräparaten zur intramuskulären Injektion. Dtsch Med Wochenschr 110:1912–1913.
Schiffer CA, Hogge DE, Aisner J, Dutcher JP, Lee EJ, Papenberg D (1984) High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients. Blood 64:937–940.
Schmidt RE, Budde U, Bröschen-Zywietz C, Schäfer G, Mueller-Eckardt C (1984) High dose gammaglobulin therapy in adults with idiopathic thrombocytopenic purpura (ITP) — Clinical effects. Blut 48:19–25.
Schulte-Wissermann H, Zepp F (1983) Indikationen und Nutzen der Immunglobulintherapie. Pädiat Prax 28:651–659.
Schultze HE, Schwick G (1962) Über neue Möglichkeiten intravenöser Gammaglobulin-Appli-kation. Dtsch Med Wochenschr 87:1643.
Schumacher K (1986) Therapie mit Immunglobulinen. Dtsch Med Wochenschr 111:550–556.
Sidiropoulos D, Straume B (1984) Treatment of neonatal isoimmune thrombocytopenia with intravenous immunoglobulin (IgG i.v.) Blut 48:383–386.
Skvaril F (1986) Clinical relevance of IgG subclasses. In: Morell A, Nydegger UE (ed) Clinical use of intravenous immunoglobulins, Academic Press, Orlando, Florida pp. 37–45.
Skvaril F, Roth-Wicky B, Barandun S (1980) IgG subclasses in human γ-globulin preparations for intravenous use and their reactivity with staphylococcus protein A. Vox Sang 38:147–155.
Stanley P, Cole P (1983) Intravenous immunoglobulin preparations. Lancet I:829.
Stephan W (1975) Undegraded human immunoglobulin för intravenous use. Vox Sang 28:422–437.
Steward MW (1984) Antibodies: Their structure and function, Chapman and Hall, London, New York.
Stiehm ER (1979) Standard and special human immune serum globulins as therapeutic agents. Pediatrics 63:301–319.
Stiehm ER (1986) Intravenous immunoglobulins in neonates and infants. Pediatr Infect Dis 5 (Suppl):217–219.
Stoll C, Schedel I, Peest D (1985) Serum antibodies against common antigens of bacterial li-popolysaccharides in healthy adults and in patients with multiple myeloma. Infection 13:23.
Sugg U, Schneider W, Hoffmeister HE, Huth C, Stephan W, Lissner R, Haase W (1985) Hepatitis B immune globulin to prevent Non-A, Non-B post-transfusion hepatitis. Lancet 1:405–406.
Sultan Y, Maisonneuve P, Kazatchkine MD, Nydegger UE (1984) Antiidiotypic suppression of autoantibodies to factor VIII (Antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 11:765–768.
Sundqvist SB, Ljung R, Holmberg L (1983) Suppression of secondary antibody response by intravenous immunoglobulin in a patient with haemophilia B and antibodies. Eur J Clin Invest 13:A42.
Tedder RS, Uttley A, Cheingsong-Popov R (1985) Safety of immunoglobulin preparation containing anti-HTLV-III. Lancet 1:815.
Tilz GP (1986) Some side effects of intravenous 7S-immunoglobulins are due to immune complexes and can be prevented by 5S-immunoglobulin given prior to 7S treatment. Clin Exp Immunol 63:258–259.
Uchino H, Yasunaga K, Akatsuka JI (1984) A cooperative clinical trial of high-dose Immunglobulin therapy in 177 cases of idiopathic thrombocytopenic purpura. Thromb Haemost 51:182–185.
Werner C (1985) Immunglobuline. Krankenhauspharmazie 6:521–523.
WHO/IUIS Report (1982) Appropriate uses of human immunoglobulin in clinical practice. Bull WHO 60:43–47.
Winston DJ, Winston G, Lin CH, Budinger MD, Champlin RD, Gale RP (1984) Intravenous immunoglobulin för modification of cytomegalovirus infections associated with bone marrow transplantation. Am J Med 76:128–133.
Wong P, Itoh K, Yoshida S (1986) Treatment of thrombotic thrombocytopenic purpura with intravenous gamma globulin. N Engl J Med 314:385–386.
Zanetti AR, Dentico P, Vecchio Blanco C del, Sagnelli E, Villa E, Ferroni P, Bergamini F (1986) Multicenter trial on the efficacy of HBIG and vaccine in preventing perinatal hepatitis B. J Med Virol 18:327–334.
Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, Braude AI (1982) Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 307:1225–1230.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Mueller-Eckhardt, C. (1988). Therapie mit Immunglobulinen. In: Mueller-Eckhardt, C. (eds) Transfusionsmedizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10601-3_22
Download citation
DOI: https://doi.org/10.1007/978-3-662-10601-3_22
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-10602-0
Online ISBN: 978-3-662-10601-3
eBook Packages: Springer Book Archive